Sophia Genetics publishes investor presentation on AI platform for precision medicine
SOPH•Full-year 2025 revenue and genomics mix
FY 2025 IFRS revenue was USD 77.27 million on 391,000 analyses; genomics represented more than 90% of annual revenue.
Investor presentation highlights AstraZeneca agreement and Q2 growth
Sophia Genetics highlighted a new multi-year AstraZeneca agreement to launch two companion diagnostic programs covering solid tumors and blood cancers.
- Q2 2026 IFRS revenue was USD 23.31 million, up 27% year-over-year; constant-currency revenue was USD 22.86 million, up 25%.
- Q2 analysis volume was 115,000, up 22% year-over-year; net dollar retention was 117%; annualized revenue churn was below 1%.
- Q2 adjusted EBITDA loss was USD 8.83 million versus USD 12.04 million a year earlier; cash balance was USD 107.7 million.
